Worldwide there are over 3 500 000 dialysis patients. Only approximately 10% of these patients are treated with Peritoneal Dialysis even though Peritoneal Dialysis is generally considered the treatment of choice by both patients and healthcare providers
Triomed is developing innovative systems to address the key limitations of Peritoneal Dialysis. Systems to ensure that Peritoneal Dialysis becomes the preferred dialysis alternative for End-Stage Kidney Disease patients, and help patients stay on Peritoneal Dialysis longer
By continually recirculating and regenerating dialysate fluid, Triomed SCPD maintains a constant osmotic gradient over the patient’s peritoneal membrane, something traditional Peritoneal Dialysis does not do.
Award winning clinical studies have shown that Triomed SCPD leads to a significant increase in the removal of water and salt from Peritoneal Dialysis patients and a significant improvement in glucose efficiency